ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2124

Serum Concentrations of Soluble Interferon Receptor in Patients with Rheumatoid Arthritis

Masao Sato1, Masao Takemura2, Ryuki Shinohe3, Tsuneo Watanabe2 and Katsuji Shimizu3, 1Rheumatology, Matsunami General Hospital, Gifu, Japan, 2Informative Clinical Medicine, Gifu University, Gifu, Japan, 3Orthopaedic Surgery, Gifu University, Gifu, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: interferons, osteoarthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Interferon (IFN) exerts antiviral and antineoplastic activities, and is involved in immunoregulatory activities. IFN probably plays an important role in the pathogenesis of rheumatoid arthritis (RA), which is a chronic and progressive inflammatory disease. IFN is eliminated from the bloodstream, with a half-life of 2 h, it is difficult to detect IFN concentrations in the sera. IFN, similar to other cytokines, exerts its biological activities by binding to cell-surface receptors. In this study, we evaluated the serum concentrations of soluble IFN α/β receptor (sIFNR) in patients with RA.

Methods:

The study involved 57 patients (11 men and 46 women) with RA who met the American College of Rheumatology 1987 RA classification criteria. The patients were aged 31 – 85 y (mean age, 61.2 y). The control group consisted of 16 patients with osteoarthritis (OA) of the knee and 216 healthy subjects, (mean age, 57.1 y and 52.3 y, respectively); the sIFNR concentrations of these subjects were determined. All the subjects recruited in this study were negative for hepatitis B surface antigens and hepatitis C antibodies. Blood samples were obtained from the subjects, and serum fractions separated from the blood samples were stored at -80 degree, until the assay was performed.

Results:

The serum concentrations of sIFNR in RA patients that varied from 0.7 to 5.8 ng/ml (mean, +/- SD: 2.1 +/- 1.2 ng/ml) and were significantly higher than those in the OA patients (mean, +/- SD: 1.4 +/- 0.7 ng/ml: p < 0.03) and the healthy subjects (mean, +/- SD: 1.0 +/- 0.5 ng/ml: p < 0.001). The serum levels of sIFNR in the RA patients with radiographic stage scores of II, III, and IV were 1.0 +/- 0.2 ng/ml, 1.3 +/- 0.3 ng/ml, and 2.5 +/- 1.2 ng/ml, respectively. The serum levels of sIFNR in the RA patients with activities of daily living (ADL) scores of 2, 3, and 4 were 1.2 +/- 0.2 ng/ml, 2.5 +/- 1.0 ng/ml, and 3.8 +/- 1.5 ng/ml, respectively. The serum levels of sIFNR in the RA patients were positively correlated with the disease durations (r = 0.55: p < 0.0001).

Conclusion:

In this study, we observed that the serum levels of sIFNR in the RA patients were significantly higher than those in the OA patients and the healthy subjects. A significant correlation was observed between the serum levels of sIFNR in the RA patients and the RA stage scores, ADL scores, and disease durations. Therefore, serum levels of sIFNR might be a useful predictor for the prognosis of chronic conditions and RA.


Disclosure:

M. Sato,
None;

M. Takemura,
None;

R. Shinohe,
None;

T. Watanabe,
None;

K. Shimizu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-concentrations-of-soluble-interferon-receptor-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology